UPLOAD Filing
Propanc Biopharma, Inc.
Date: April 15, 2026 · CIK: 0001517681 · Accession: 0000000000-26-003828
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295002
Letter
Re: Propanc Biopharma, Inc. Registration Statement on Form S-1 Filed April 10, 2026 File No. 333-295002 Dear James Nathanielsz:
April 15, 2026
James Nathanielsz Chief Executive Officer Propanc Biopharma, Inc. 302, 6 Butler Street Camberwell, VIC 3124 Australia
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Chase Chandler, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 15, 2026 James Nathanielsz Chief Executive Officer Propanc Biopharma, Inc. 302, 6 Butler Street Camberwell, VIC 3124 Australia Re: Propanc Biopharma, Inc. Registration Statement on Form S-1 Filed April 10, 2026 File No. 333-295002 Dear James Nathanielsz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Chase Chandler, Esq. </TEXT> </DOCUMENT>